{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:34:15Z","timestamp":1781602455017,"version":"3.54.5"},"reference-count":38,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Archives of Disease in Childhood"],"published-print":{"date-parts":[[2014,6,1]]},"DOI":"10.1136\/archdischild-2013-304601","type":"journal-article","created":{"date-parts":[[2014,2,4]],"date-time":"2014-02-04T03:54:30Z","timestamp":1391486070000},"page":"505-510","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of chronic viral hepatitis C in children and adolescents: UK experience"],"prefix":"10.1136","volume":"99","author":[{"given":"M.","family":"Abdel-Hady","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Tizzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mieli-Vergani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,2,3]]},"reference":[{"issue":"(s1)","key":"key-10.1136\/archdischild-2013-304601-1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver International"},{"key":"key-10.1136\/archdischild-2013-304601-2","doi-asserted-by":"crossref","DOI":"10.1093\/eurpub\/ckr083","article-title":"Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis","author":"Harris","year":"2012","journal-title":"Eur J Public Health"},{"key":"key-10.1136\/archdischild-2013-304601-3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/01.mpg.0000228117.52229.32","article-title":"Hepatitis C in children: quaternary referral centre perspective","volume":"43","author":"Rumbo","year":"2006","journal-title":"J Pediatr gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-304601-4","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long-Term course of Chronic Hepatitis C in Children: from viral clearance to End-Stage Liver Disease","volume":"134","author":"Bortollotti","year":"2008","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-304601-5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1572-0241.2003.07293.x","article-title":"Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?","volume":"98","author":"Guido","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key-10.1136\/archdischild-2013-304601-6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jpeds.2005.10.031","article-title":"The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period","volume":"148","author":"Jhaveri","year":"2006","journal-title":"J Pediatr"},{"key":"key-10.1136\/archdischild-2013-304601-7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"key-10.1136\/archdischild-2013-304601-8","volume-title":"Child Health Questionnaire (CHQ): A User's Manual","author":"Landgraf","year":"1999"},{"key":"key-10.1136\/archdischild-2013-304601-9","unstructured":"Chief Medical Officer, Department of Health. PL CMO: Hepatitis C and blood transfusion look back. 1995."},{"key":"key-10.1136\/archdischild-2013-304601-10","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1111\/j.1365-2893.2011.01456.x","article-title":"Chronic hepatitis C in children-review of natural history at a national centre","volume":";18","author":"Abdel-Hady","year":"2011","journal-title":"J Viral Hepat"},{"key":"key-10.1136\/archdischild-2013-304601-11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"key-10.1136\/archdischild-2013-304601-12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2010.01.016","article-title":"High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin","volume":"52","author":"Wirth","year":"2010","journal-title":"J Hepatol"},{"issue":"(Suppl C)","key":"key-10.1136\/archdischild-2013-304601-13","first-page":"25C","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: consensus guidelines","volume":"21","author":"Hadziyannis","year":"2007","journal-title":"Can J gastroenterol"},{"key":"key-10.1136\/archdischild-2013-304601-14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","article-title":"Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection","volume":"27","author":"Jara","year":"2008","journal-title":"Pediatr Infec Dis J"},{"key":"key-10.1136\/archdischild-2013-304601-15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MCG.0b013e31802dd2f6","article-title":"Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C","volume":"41","author":"Baker","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"key-10.1136\/archdischild-2013-304601-16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2010.01.028","article-title":"Peginterferon alpha-2a plus ribavirin for chronic Hepatitis C virus infection in children and adolescents","volume":"52","author":"Sokal","year":"2010","journal-title":"J Hepatolo"},{"key":"key-10.1136\/archdischild-2013-304601-17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.gastro.2010.10.047","article-title":"The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C","volume":"140","author":"Schwarz","year":"2011","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-304601-18","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/hep.20661","article-title":"Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C","volume":"41","author":"Wirth","year":"2005","journal-title":"Hepatology"},{"key":"key-10.1136\/archdischild-2013-304601-19","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.20884","article-title":"Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children. Efficacy, safety, and pharmacokinetics","volume":"42","author":"Gonzalez-Peraltaa","year":"2005","journal-title":"Hepatology."},{"key":"key-10.1136\/archdischild-2013-304601-20","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1053\/jhep.2002.36495","article-title":"Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C","volume":"36","author":"Wirth","year":"2002","journal-title":"Hepatology"},{"issue":"(Supp 2)","key":"key-10.1136\/archdischild-2013-304601-21","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/S0168-8278(08)60993-9","article-title":"Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study","volume":"48","author":"Sulkowski","year":"2008","journal-title":"J Hepatol."},{"key":"key-10.1136\/archdischild-2013-304601-22","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid Virological Response and Treatment Duration for Chronic Hepatitis C Genotype 1 Patients: A Randomized Trial","volume":"47","author":"Ming-Yung","year":"2008","journal-title":"Hepatology"},{"key":"key-10.1136\/archdischild-2013-304601-23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","article-title":"Expert opinion on the treatment of patients with chronic hepatitis C","volume":"16","author":"Zeuzem","year":"2009","journal-title":"J Viral Hepat"},{"key":"key-10.1136\/archdischild-2013-304601-24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/hep.21917","article-title":"Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response","volume":"46","author":"Kamal","year":"2007","journal-title":"Hepatology"},{"key":"key-10.1136\/archdischild-2013-304601-25","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa042608","article-title":"Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3","volume":"352","author":"Mangia","year":"2005","journal-title":"N Engl J Med"},{"key":"key-10.1136\/archdischild-2013-304601-26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"key-10.1136\/archdischild-2013-304601-27","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"key-10.1136\/archdischild-2013-304601-28","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"key-10.1136\/archdischild-2013-304601-29","doi-asserted-by":"crossref","first-page":"1338e45","DOI":"10.1053\/j.gastro.2009.12.056","article-title":"Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study","volume":"138","author":"Rauch","year":"2010","journal-title":"Gastroenterology"},{"key":"key-10.1136\/archdischild-2013-304601-30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.07.037","article-title":"Pre-treatment prediction of response to pegylated interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors","volume":"54","author":"Kurosaki","year":"2011","journal-title":"J Hepatol"},{"key":"key-10.1136\/archdischild-2013-304601-31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/0897190010367737","article-title":"Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: A preliminary study","volume":"24","author":"Abdel-Aziz","year":"2011","journal-title":"J Pharm Prac"},{"key":"key-10.1136\/archdischild-2013-304601-32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/1319-3767.27847","article-title":"Neuropsychiatric side-effects of interferon alfa therapy for hepatitis C and their management: a review","volume":"12","author":"Al-Huthail","year":"2006","journal-title":"Saudi J Gastroenterol"},{"key":"key-10.1136\/archdischild-2013-304601-33","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MPG.0b013e3181f6f09c","article-title":"Guidance for clinical trials for children and adolescents with chronic hepatitis C","volume":"52","author":"Wirth","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-304601-34","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/MPG.0b013e318258328d","article-title":"NASPGHAN Practice Guidelines: Diagnosis and Management of Hepatitis C Infection in Infants, Children, and Adolescents","volume":"54","author":"Mack","year":"2012","journal-title":"J pediatr gastroenterol Nutr"},{"key":"key-10.1136\/archdischild-2013-304601-35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2893.2011.01544.x","article-title":"Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin","volume":"19","author":"Kelly","year":"2012","journal-title":"J Viral Hepat"},{"key":"key-10.1136\/archdischild-2013-304601-36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","article-title":"Reduction of health related quality of life in chronic hepatitis C and improvement with interferon therapy: The Consensus Interferon Study Group","volume":"29","author":"Bonkovsky","year":"1999","journal-title":"Hepatology"},{"key":"key-10.1136\/archdischild-2013-304601-37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2002.30688","article-title":"Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease","volume":"35","author":"Forton","year":"2002","journal-title":"Hepatology"},{"key":"key-10.1136\/archdischild-2013-304601-38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/hep.24248","article-title":"Peginterferon with or without ribavirin has minimal effect on quality of life, behavioural\/emotional, and cognitive outcomes in children","volume":"53","author":"Rodrigue","year":"2011","journal-title":"Hepatology"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2013-304601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T06:16:32Z","timestamp":1648188992000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2013-304601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,3]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,5,15]]},"published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1136\/archdischild-2013-304601","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,3]]}}}